These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Recombinant soluble IFN receptor (sIFNAR2) exhibits intrinsic therapeutic efficacy in a murine model of Multiple Sclerosis. Suardíaz M; Clemente D; Marin-Bañasco C; Orpez T; Hurtado-Guerrero I; Pavía J; Pinto-Medel MJ; De Castro F; Leyva L; Fernández O; Oliver B Neuropharmacology; 2016 Nov; 110(Pt A):480-492. PubMed ID: 27452720 [TBL] [Abstract][Full Text] [Related]
7. Multiple sclerosis: expression of CD1a and production of IL-12p70 and IFN-gamma by blood mononuclear cells in patients on combination therapy with IFN-beta and glatiramer acetate compared to monotherapy with IFN-beta. Hussien Y; Sanna A; Söderström M; Link H; Huang YM Mult Scler; 2004 Feb; 10(1):16-25. PubMed ID: 14760948 [TBL] [Abstract][Full Text] [Related]
8. Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients. Johnson BH; Bonafede MM; Watson C CNS Drugs; 2015 Jun; 29(6):503-10. PubMed ID: 26113055 [TBL] [Abstract][Full Text] [Related]
9. Effects of interferon and glatiramer acetate on cytokine patterns in multiple sclerosis patients. Ganji A; Monfared ME; Shapoori S; Nourbakhsh P; Ghazavi A; Ghasami K; Mosayebi G Cytokine; 2020 Feb; 126():154911. PubMed ID: 31731047 [TBL] [Abstract][Full Text] [Related]
10. Association between soluble L-selectin and anti-JCV antibodies in natalizumab-treated relapsing-remitting MS patients. Basnyat P; Hagman S; Kolasa M; Koivisto K; Verkkoniemi-Ahola A; Airas L; Elovaara I Mult Scler Relat Disord; 2015 Jul; 4(4):334-8. PubMed ID: 26195052 [TBL] [Abstract][Full Text] [Related]
11. The low EOMES/TBX21 molecular phenotype in multiple sclerosis reflects CD56+ cell dysregulation and is affected by immunomodulatory therapies. McKay FC; Gatt PN; Fewings N; Parnell GP; Schibeci SD; Basuki MA; Powell JE; Goldinger A; Fabis-Pedrini MJ; Kermode AG; Burke T; Vucic S; Stewart GJ; Booth DR Clin Immunol; 2016 Feb; 163():96-107. PubMed ID: 26762769 [TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up for multiple sclerosis patients initially treated with interferon-beta and glatiramer acetate. Healy BC; Glanz BI; Zurawski JD; Mazzola M; Chitnis T; Weiner HL J Neurol Sci; 2018 Nov; 394():127-131. PubMed ID: 30248571 [TBL] [Abstract][Full Text] [Related]
14. Alterations in serum levels of IL-17 in contrast to TNF-alpha correspond to disease-modifying treatment in relapsing-remitting multiple sclerosis. Trenova AG; Slavov GS; Manova MG; Draganaova-Filipova MN; Mateva NG; Miteva LD; Stanilova SA Scand J Clin Lab Invest; 2017 Jul; 77(4):283-288. PubMed ID: 28319417 [TBL] [Abstract][Full Text] [Related]
15. MTR recovery in brain lesions in the BECOME study of glatiramer acetate vs interferon β-1b. Brown RA; Narayanan S; Stikov N; Cook S; Cadavid D; Wolansky L; Arnold DL Neurology; 2016 Aug; 87(9):905-11. PubMed ID: 27473139 [TBL] [Abstract][Full Text] [Related]
16. Differential Transcription of SOCS5 and SOCS7 in Multiple Sclerosis Patients Treated with Interferon Beta or Glatiramer Acetate. Rojas-Morales E; Santos-López G; Hernández-Cabañas S; Arcega-Revilla R; Rosas-Murrieta N; Jasso-Miranda C; El-Kassis EG; Reyes-Leyva J; Sedeño-Monge V Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31905601 [TBL] [Abstract][Full Text] [Related]